The MAPK signaling pathway is regulated by the following microRNAs: MiR-148a targets Insulin-like
growth factor-I receptor (IGF-IR) and MAP3K9 to suppress ERK/MAPK cascade. In esophageal SCC,
miR-148a targets MAP3K9 to decrease activity of ERK/MAPK pathway. MiR-494, miR-379 and miR-7
modulate the SOS2/MAPK/ERK signaling axis and suppress ERK/MAPK pathway. MiR-101
suppresses proliferation and metastasis of cancer cells through suppressing ZFX expression and
reducing activity of the ERK/MAPK and Smad pathways. MiR‐140‐3p inhibits the MAPK signaling
pathway through down-regulating GRN. MiR-217, miR-302a and miR-152 suppress the activity of
ERK/MAPK signaling, thus reducing cell proliferation and invasion by reducing phosphorylation of
MEK1/2, p44/42 MAPK (ERK1/2) and Akt at Ser473. MiR-29c-5p induces apoptosis via modulation of
MAPK/ERK pathway partly by increased cleavages of caspase-9, caspase-3, and PARP. MiR-543
suppresses activity of ERK2, thus inhibiting tumor growth. MiR-550a-3p down-regulates ERK1/ERK2
and suppresses the ERK/RSK cascades, resulting in decreased migration, invasion, tumorigenesis,
and metastasis of cancer cells. Let-7a are exerted through modulation of KRas/NF-kB and
KRas/MEK/ERK pathways. MiR-214 enhances p-ERK level and p-ERK/ERK to induce activity of the
ERK/MAPK signaling pathway. This miRNA also increases PCNA level, and reduces p21 level, thus
increasing cell proliferation and suppressing cell apoptosis. MiR-330-5p increases the activity of the
ERK/MAPK pathway through targeting SPRY2. MiRNA-128 and miR-330-3p activate MAPK
signalling through GAREM-mediation and inhibits GRIA3 expression. The miR-200 family modulates
expression of RASSF2, the negative regulator of KRAS.